Literature DB >> 9447299

Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy.

T Wasada1, K Aoki, A Sato, K Katsumori, K Muto, O Tomonaga, H Yokoyama, N Iwasaki, T Babazono, C Takahashi, Y Iwamoto, Y Omori, N Hizuka.   

Abstract

With a euglycemic hyperinsulinemic clamp method, whole-body insulin resistance was assessed in 6 cases with acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. The glucose infusion rate (GIR) correlated well with the plasma IGF-I level but poorly with that of GH. Further improvement in insulin sensitivity occurred 3-4 months after operation without substantial changes in plasma levels of both GH and IGF-I or glycemic control. These results indicate that GH excess can induce insulin resistance in association with plasma IGF-I and also through undefined secondary effect.

Entities:  

Mesh:

Year:  1997        PMID: 9447299     DOI: 10.1507/endocrj.44.617

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

Review 2.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels.

Authors:  K Mori; Y Iwasaki; Y Kawasaki-Ogita; S Honjo; Y Hamamoto; H Tatsuoka; K Fujimoto; H Ikeda; Y Wada; Y Takahashi; J Takahashi; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-05-10       Impact factor: 4.256

4.  The ability of β-cells to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients.

Authors:  Soo Kyoung Kim; Sunghwan Suh; Ji In Lee; Kyu Yeon Hur; Jae Hoon Chung; Moon-Kyu Lee; Yong-Ki Min; Jae Hyeon Kim; Jong-Hyun Kim; Kwang-Won Kim
Journal:  J Korean Med Sci       Date:  2012-01-27       Impact factor: 2.153

5.  Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.

Authors:  Vikram Singh Shekhawat; Shobhit Bhansali; Pinaki Dutta; Kanchan Kumar Mukherjee; Kim Vaiphei; Rakesh Kochhar; Saroj K Sinha; Naresh Sachdeva; Anura V Kurpad; Kishor Bhat; Sunder Mudaliar; Anil Bhansali
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

6.  The Beta-Cell Function and Glucose Profile of Newly Diagnosed Acromegalic Patients with Normal Glucose Tolerance.

Authors:  Quanya Sun; Xiaoqing Li; Peili Chen; Lili Chen; Xiaolong Zhao
Journal:  Int J Endocrinol       Date:  2021-12-07       Impact factor: 3.257

7.  Serum resistin and insulin-like growth factor-1 levels in patients with hypothyroidism and hyperthyroidism.

Authors:  Ceren Eke Koyuncu; Sembol Turkmen Yildirmak; Mustafa Temizel; Tevfik Ozpacaci; Pinar Gunel; Mustafa Cakmak; Yüksel Gülen Ozbanazi
Journal:  J Thyroid Res       Date:  2013-02-24

8.  Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly.

Authors:  Julia Szendroedi; Elisabeth Zwettler; Albrecht Ingo Schmid; Marek Chmelik; Giovanni Pacini; Gertrud Kacerovsky; Gerhard Smekal; Peter Nowotny; Oswald Wagner; Christoph Schnack; Guntram Schernthaner; Klaus Klaushofer; Michael Roden
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

9.  The contribution of visceral fat to improved insulin signaling in Ames dwarf mice.

Authors:  Vinal Menon; Xu Zhi; Tanvir Hossain; Andrzej Bartke; Adam Spong; Adam Gesing; Michal M Masternak
Journal:  Aging Cell       Date:  2014-02-12       Impact factor: 9.304

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.